

UFCW Union & P E HW Fund Catamaran 2013 Calendar Year Review



Catamaran Spotlight: *Mobile App*

The Catamaran Mobile App provides easy, on-the-go access to members' personalized health information.







- Never miss a dose, set reminders to take your prescriptions or OTC medications
- Stay on top of medication refills. See when refills are due, get refill reminders and quickly contact your pharmacy
- Show your doctors what medications you're taking
- Pull up your medication history any time
- Learn about medication side effects and interactions
- Find network pharmacies by zip code or location, then check and compare current prescription prices
- Order refills from Catamaran Home Delivery



plan performance review

plan performance review

client landscape - UFCW Union & P E HW Fund





key performance


	UFCW Union & P E HW Fund			Book of Business: Catamaran		Industry: UFCW	
Description	Jan 13 - Dec 13	Jan 12 - Dec 12	% Change	Jan 13 - Dec 13	% Change	Jan 13 - Dec 13	% Change
Average Eligible Members	4,887	5,259	-7.1%				
Average Age	43.1	42.4	1.8%	36.7	-0.5%	38.7	1.5%
Percent Total Utilizers	73.4%	72.2%	1.7%	76.6%	0.2%	67.6%	8.9%
Total Plan Paid	\$6,077,280	\$5,963,653	1.9%				
Total Rx's	63,408	68,045	-6.8%				
Plan Paid PMPM	\$103.62	\$94.49	9.7%	\$55.64	4.0%	\$62.69	3.0%
Plan Paid per Rx	\$95.84	\$87.64	9.4%	\$64.49	3.8%	\$74.13	-1.0%
Rx's PMPM	1.08	1.08	0.3%	0.86	0.2%	0.85	4.0%
Days Supply PMPM	38.7	37.8	2.4%	28.3	1.9%	29.9	4.9%
Member Cost Share	7.8%	7.8%	-0.4%	18.9%	-6.3%	14.8%	1.0%
Generic Dispensing Rate	74.8%	73.0%	2.6%	82.0%	3.3%	81.0%	4.4%
Average Days Supply	35.8	35.1	2.2%	32.8	1.7%	35.3	0.9%
Specialty Plan Paid PMPM	\$18.86	\$14.38	31.1%	\$15.07	13.9%	\$14.03	19.5%
Percent of Specialty Plan Paid	18.2%	15.2%	19.6%	27.1%	9.5%	22.4%	16.0%

traditional vs specialty - UFCW Union & P E HW Fund

Description	Traditional			Specialty		
	Jan 13 - Dec 13	Jan 12 - Dec 12	% Change	Jan 13 - Dec 13	Jan 12 - Dec 12	% Change
Average Eligible Members	4,887	5,259	-7.1%	4,887	5,259	-7.1%
Total Utilizers	3,585	3,791	-5.4%	95	92	3.3%
Total Plan Paid	\$4,971,232	\$5,056,022	-1.7%	\$1,106,049	\$907,631	21.9%
Percent of Total Plan Paid	81.8%	84.8%	-3.5%	18.2%	15.2%	19.6%
Total Rx's	62,652	67,323	-6.9%	756	722	4.7%
Plan Paid PMPM	\$84.77	\$80.11	5.8%	\$18.86	\$14.38	31.1%
Plan Paid per Rx	\$79.35	\$75.10	5.7%	\$1,463.03	\$1,257.11	16.4%
Rxs PMPM	1.07	1.07	0.1%	0.013	0.011	12.7%
Days Supply PMPM	38.4	37.5	2.3%	0.385	0.339	13.7%
Generic Dispensing Rate	75.5%	73.4%	2.8%	25.0%	33.9%	-26.3%
Member Cost Share	7.8%	7.9%	-0.6%	7.6%	7.5%	1.4%
Copay per Rx	\$6.73	\$6.41	5.0%	\$120.23	\$101.80	18.1%

Specialty represents 1.9% of the total members, but 18.2% of the total paid by the plan.


Specialty Pharm are pharmacies that primarily dispense only specialty drugs





trend components - UFCW Union & P E HW Fund

Components of Trend	Jan 13 - Dec 13 vs Jan 12 - Dec 12		
	Impact of Change	Change in Plan Paid PMPM	UFCW: Impact of Change
Utilization - Rx Cnt	0.9%	\$0.83	4.3%
Utilization - Drug Mix	0.5%	\$0.46	-7.0%
Quantity	1.1%	\$1.05	0.3%
Unit Cost	7.2%	\$6.79	5.4%
Total	9.7%	\$9.13	3.0%



top therapy class by plan paid - UFCW Union & P E HW Fund

Jan 13 - Dec 13											
Curr Rank	Prev Rank	Therapeutic Class Name	Plan Paid	Rxs	Plan Paid per Rx	GDR	UFCW GDR	Plan Paid / PMPM	Avg Plan Paid Pct Chg	Utilization Rate Pct Chg	Plan Paid PMPM Pct Chg
1	2	ANTIDIABETICS	\$579,895	3,603	\$160.95	57.4%	62.5%	\$9.89	10.0%	-5.0%	12.4%
2	1	ANTIHYPERLIPIDEMICS	\$565,306	4,545	\$124.38	67.8%	78.2%	\$9.64	0.4%	-7.1%	0.3%
3	6	ANTIVIRALS	\$432,146	804	\$537.49	48.4%	62.9%	\$7.37	16.0%	10.0%	37.3%
4	4	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$414,619	2,926	\$141.70	27.3%	26.7%	\$7.07	-0.3%	-0.3%	7.0%
5	3	ANTIHYPERTENSIVES	\$403,292	5,630	\$71.63	77.3%	87.6%	\$6.88	1.1%	-5.3%	3.1%
6	5	ULCER DRUGS	\$367,281	2,703	\$135.88	57.2%	76.6%	\$6.26	10.8%	-10.0%	7.3%
7	7	ANALGESICS - OPIOID	\$277,604	4,888	\$56.79	91.9%	94.4%	\$4.73	9.7%	-9.2%	7.2%
8	8	ANTIDEPRESSANTS	\$250,054	3,080	\$81.19	84.3%	89.8%	\$4.26	-4.7%	-3.1%	-0.6%
9	9	ANTINEOPLASTICS	\$211,455	249	\$849.22	84.7%	90.1%	\$3.61	17.4%	-13.5%	9.2%
10	14	ASSORTED CLASSES	\$206,715	128	\$1,614.96	81.3%	77.2%	\$3.52	113.8%	-34.0%	51.8%
Totals:			\$3,708,366	28,556	\$129.86	68.8%		\$63.23	9.1%	-5.9%	10.5%
Plan Totals:			\$6,077,280	63,408	\$95.84	74.8%	81.0%	\$103.62	9.4%	-6.8%	9.7%

- The Top therapy categories represent **45%** of the overall claims and **61%** of the plan paid
- **Antidiabetics** ranked #1 with a 12.4% trend increase due to utilization and cost i.e. Lantus solastar; Januvia
- **Antihyperlipidemics** ranked #2 with a slight increase of 0.3% - Lipitor became generic in 2013
- **Antivirals** ranked #3 with a 37.3% trend increase with a 10% increase in utilization i.e. specialty drugs for HIV – Atripla, Complera, Viread
- **Antiasthmatics/Bronchodilating agents** ranked #4 with a 7% trend increase i.e. Advair, Spiriva
- **Analgesics Opioids** - pain medications/narcotics with 7.2% trend increase i.e. Oxycontin, Hydrocodone/acetaminophen, Oxycodone/acetaminophen
- **Antineoplastics** – cancer drugs with a 9.2% trend increase due to specialty drug use – Gleevec, Afinitor
- **Assorted classes** – 51.8% trend increase due to specialty drug - i.e. Revlimid



top drugs by plan paid - UFCW Union & P E HW Fund

Jan 13 - Dec 13										
Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Plan Paid	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Utilization Rate Pct Chg	Plan Paid PMPM Pct Chg	Pct Total Plan Paid
1	3	CRESTOR	ANTIHYPERLIPIDEMICS	\$184,750	768	\$240.56	\$3.15	2.0%	20.5%	3.0%
2	2	NEXIUM	ULCER DRUGS	\$183,466	600	\$305.78	\$3.13	-12.8%	9.4%	3.0%
3	6	REVLIMID	ASSORTED CLASSES	\$176,181	22	\$8,008.25	\$3.00	57.1%	127.5%	2.9%
4	1	ATORVASTATIN CALCIUM	ANTIHYPERLIPIDEMICS	\$162,686	1,443	\$112.74	\$2.77	-5.1%	-19.7%	2.7%
5	5	CYMBALTA	ANTIDEPRESSANTS	\$123,520	364	\$339.34	\$2.11	-19.8%	15.4%	2.0%
6	4	ADVAIR DISKUS	ASTHMATIC AND BRONCHODILATOR AGENTS	\$102,520	358	\$286.37	\$1.75	-20.8%	-4.5%	1.7%
7	27	HUMIRA	ANALGESICS - ANTI-INFLAMMATORY	\$84,668	33	\$2,565.69	\$1.44	50.0%	111.0%	1.4%
8	11	SPIRIVA HANDIHALER	ASTHMATIC AND BRONCHODILATOR AGENTS	\$77,893	279	\$279.19	\$1.33	4.1%	25.3%	1.3%
9	13	ATRIPLA	ANTIVIRALS	\$70,472	52	\$1,355.24	\$1.20	-3.7%	14.4%	1.2%
10	22	LANTUS SOLOSTAR	ANTIDIABETICS	\$69,731	222	\$314.10	\$1.19	16.2%	63.0%	1.1%
11	12	GLEEVEC	ANTINEOPLASTICS	\$69,376	11	\$6,306.93	\$1.18	-8.3%	12.3%	1.1%
12	10	JANUVIA	ANTIDIABETICS	\$67,648	195	\$346.91	\$1.15	-14.1%	8.5%	1.1%
13	7	OXYCONTIN	ANALGESICS - OPIOID	\$65,433	170	\$384.90	\$1.12	-8.1%	-10.0%	1.1%
14	16	CELEBREX	ANALGESICS - ANTI-INFLAMMATORY	\$62,202	313	\$198.73	\$1.06	-5.7%	25.9%	1.0%
15	17	DIOVAN	ANTIHYPERTENSIVES	\$61,848	300	\$206.16	\$1.05	-5.1%	26.2%	1.0%
16	9	ACIPHEX	ULCER DRUGS	\$59,579	162	\$367.77	\$1.02	-25.0%	-4.6%	1.0%
17	19	SOMAVERT	ENDOCRINE AND METABOLIC AGENTS - MISC.	\$57,072	12	\$4,755.97	\$0.97	0.0%	18.6%	0.9%
18	8	AFINITOR	ANTINEOPLASTICS	\$56,991	7	\$8,141.58	\$0.97	-30.0%	-17.8%	0.9%
19	18	LYRICA	ANTICONVULSANTS	\$55,513	179	\$310.13	\$0.95	-18.6%	15.3%	0.9%
20	21	SOMATULINE DEPOT	ENDOCRINE AND METABOLIC AGENTS - MISC.	\$50,761	12	\$4,230.12	\$0.87	0.0%	14.0%	0.8%
Totals:				\$1,842,311	5,502	\$334.84	\$31.41	-7.7%	15.9%	30.3%
Plan Totals:				\$6,077,280	63,408	\$95.84	\$103.62	-6.8%	9.7%	

- The top drugs by plan paid represent **8.7%** of the overall claims and **30.3%** of the plan paid
- **Crestor** ranked #1 – brand cholesterol drug with a 20.5% trend increase – 3.0% of the plan paid
- **Nexium** ranked #2 – brand ulcer drug with a 9.4% trend increase – 3.0% of the plan paid
- **Revlimid** ranked #3 – **specialty drug** for the treatment of mantle cell lymphoma – form of blood cancer with **127.5%** trend increase
- **Atorvastatin** ranked #4 – represent utilization of Lipitor generic in 2013 – 19.7% trend decrease
- **Humira** ranked #7 from #27 – **111%** trend increase with 50% increase in utilization – specialty drug for Rheumatoid arthritis -
- **Lantus solostar** – insulin product with 63% trend increase due to increase utilization by 16.2%
- **Gleevec and Afinitor** are specialty drugs for cancers and represent 2% of plan paid aggregated together



top specialty drugs by plan paid - UFCW Union & P E HW Fund

Jan 13 - Dec 13										
Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Plan Paid	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Utilization Rate Pct Chg	Plan Paid PMPM Pct Chg	Pct of Specialty Plan Paid
1	1	REVLIMID	ASSORTED CLASSES	\$176,181	22	\$8,008.25	\$3.00	57.1%	127.5%	15.9%
2	8	HUMIRA	ANALGESICS - ANTI-INFLAMMATORY	\$84,668	33	\$2,565.69	\$1.44	50.0%	111.0%	7.7%
3	4	ATRIPLA	ANTIVIRALS	\$70,472	52	\$1,355.24	\$1.20	-3.7%	14.4%	6.4%
4	3	GLEEVEC	ANTINEOPLASTICS	\$69,376	11	\$6,306.93	\$1.18	-8.3%	12.3%	6.3%
5	5	SOMAVERT	ENDOCRINE AND METABOLIC AGENTS - MISC.	\$57,072	12	\$4,755.97	\$0.97	0.0%	18.6%	5.2%
6	2	AFINITOR	ANTINEOPLASTICS	\$56,991	7	\$8,141.58	\$0.97	-30.0%	-17.8%	5.2%
7	6	SOMATULINE DEPOT	ENDOCRINE AND METABOLIC AGENTS - MISC.	\$50,761	12	\$4,230.12	\$0.87	0.0%	14.0%	4.6%
8	28	STRIBILD	ANTIVIRALS	\$46,004	21	\$2,190.67	\$0.78	600.0%	671.3%	4.2%
9	27	COMPLERA	ANTIVIRALS	\$41,245	24	\$1,718.54	\$0.70	500.0%	563.7%	3.7%
10	9	VIREAD	ANTIVIRALS	\$38,797	61	\$636.01	\$0.66	1.7%	9.1%	3.5%
Totals:				\$691,568	255	\$2,712.03	\$11.79	25.6%	53.5%	62.5%
Plan Specialty Totals:				\$1,106,049	756	\$1,463.03	\$18.86	4.7%	31.1%	

- The top specialty drugs represent **33.7%** of the specialty claims and **62.5%** of the specialty plan paid
- **Revlimid** – treatment of anemia due to myelodysplastic syndrome and mantle cell lymphoma – 127.5% trend increase - \$8,008.25 per Rx
- **Humira** – injectable drug - treatment of Rheumatoid arthritis, ankylosing spondylitis, Crohn's disease – 111% trend increase due to increased utilization
- **Atripla** – HIV medication
- **Gleevec** – cancer drug for the treatment of leukemia and gastrointestinal tumors
- **Somavert** – treats a growth hormone disorder that can not be treated with surgery or radiation
- **Afinitor** – treats advanced kidney cancer - \$8,141.58 per Rx
- **Somatuline depot** –long term treatment of acromegaly - a growth hormone disorder that can not be treated with surgery or radiation - \$4,230.12 per Rx
- **Stribild, Complera, Viread**–HIV medications

All Enbrel products, Humira products, Avonex products and Pegasys products have been aggregated together

top drugs by rxs - UFCW Union & P E HW Fund

Jan 13 - Dec 13										
Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Plan Paid	Rxs	Plan Paid Per Rx	Plan Paid PMPM	Utilization Rate Pct Chg	Plan Paid PMPM Pct Chg	Pct Total Plan Paid
1	1	LISINAPRIL	ANTIHYPERTENSIVES	\$11,885	1,511	\$7.87	\$0.20	-1.9%	7.8%	0.2%
2	2	ATORVASTATIN CALCIUM	ANTIHYPERLIPIDEMICS	\$162,686	1,443	\$112.74	\$2.77	-5.1%	-19.7%	2.7%
3	5	AMLODIPINE BESYLATE	CALCIUM CHANNEL BLOCKERS	\$17,356	1,236	\$14.04	\$0.30	1.0%	9.7%	0.3%
4	3	HYDROCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	\$11,280	1,165	\$9.68	\$0.19	-21.5%	-5.9%	0.2%
5	4	OXYCODONE/ACETAMINOPHEN	ANALGESICS - OPIOID	\$30,970	1,047	\$29.58	\$0.53	-15.6%	25.1%	0.5%
6	8	LEVOTHYROXINE SODIUM	THYROID AGENTS	\$10,133	1,004	\$10.09	\$0.17	2.6%	21.1%	0.2%
7	9	METFORMIN HCL	ANTIDIABETICS	\$12,580	978	\$12.86	\$0.21	2.2%	16.4%	0.2%
8	6	IBUPROFEN	ANALGESICS - ANTI-INFLAMMATORY	\$4,053	922	\$4.40	\$0.07	-11.7%	-8.1%	0.1%
9	7	HYDROCHLOROTHIAZIDE	DIURETICS	\$3,993	907	\$4.40	\$0.07	-11.3%	1.7%	0.1%
10	13	CRESTOR	ANTIHYPERLIPIDEMICS	\$184,750	768	\$240.56	\$3.15	2.0%	20.5%	3.0%
11	12	AMOXICILLIN	PENICILLINS	\$3,664	729	\$5.03	\$0.06	-7.4%	-1.8%	0.1%
12	21	VITAMIN D	VITAMINS	\$7,990	725	\$11.02	\$0.14	27.0%	24.8%	0.1%
13	11	SIMVASTATIN	ANTIHYPERLIPIDEMICS	\$5,090	722	\$7.05	\$0.09	-15.6%	-14.8%	0.1%
14	10	AZITHROMYCIN	MACROLIDES	\$11,006	692	\$15.90	\$0.19	-20.2%	-15.9%	0.2%
15	18	TRAMADOL HCL	ANALGESICS - OPIOID	\$7,028	666	\$10.55	\$0.12	4.7%	12.3%	0.1%
16	19	PANTOPRAZOLE SODIUM	ULCER DRUGS	\$13,693	615	\$22.26	\$0.23	-0.5%	21.4%	0.2%
17	23	METOPROLOL SUCCINATE ER	BETA BLOCKERS	\$30,895	607	\$50.90	\$0.53	7.4%	15.0%	0.5%
18	14	ALPRAZOLAM	ANTI-ANXIETY AGENTS	\$2,703	603	\$4.48	\$0.05	-14.1%	-10.7%	0.0%
19	15	NEXIUM	ULCER DRUGS	\$183,466	600	\$305.78	\$3.13	-12.8%	9.4%	3.0%
20	17	CYCLOBENZAPRINE HCL	MUSCULOSKELETAL THERAPY AGENTS	\$3,669	596	\$6.16	\$0.06	-9.3%	0.0%	0.1%
Totals:				\$718,891	17,536	\$41.00	\$12.26	-6.3%	3.5%	11.8%
Plan Totals:				\$6,077,280	63,408	\$95.84	\$103.62	-6.8%	9.7%	

The top drugs by volume (# of Rxs) represent **27.7%** of the overall claims and **11.8%** of the plan paid

All Enbrel products, Humira products, Avonex products and Pegasys products have been aggregated together



UFCW Union & P E HW Fund					
Value of Higher Generic Utilization					
Jan 13 - Dec 13					
	Retail 30		Retail 90		Total
Current Generic Dispensing Rate	74.0%		82.1%		75.5%
Previous Generic Dispensing Rate	72.4%		78.4%		73.4%
Change in Generic Dispensing Rate	1.7%		3.7%		2.1%
Generic Plan Paid per Rx	\$28.57		\$67.07		\$35.90
Brand Plan Paid per Rx	\$184.63		\$405.49		\$212.87
Average Plan Paid Savings per Rx	\$156.06		\$338.42		\$176.97
Total Plan Savings	\$133,148		\$136,179		\$269,327
			% Savings		4.2%
Every 1% Increase in Generic Utilization Saves:					2.1%

Notes

Specialty excluded in analysis

Savings includes effect of natural switch to generics

The generic dispensing rate at **75.5%** with a **2.1%** increase – savings of
\$269,327
Every 1% increase in generic utilization saves 2.1% of the plan paid



Fastest Moving Drugs: Highest Plan Paid Per Member Change - UFCW Union & P E HW Fund

				Jan 13 - Dec 13			Jan 12 - Dec 12			% Change Plan Paid / Mbr
Curr Rank	Prev Rank	Drug Name	Therapeutic Class Name	Plan Paid	Rxs	Plan Paid / Rx	Plan Paid	Rxs	Plan Paid / Rx	
28	191	STRIBILD	ANTIVIRALS	\$46,004	21	\$2,190.67	\$6,419	3	\$2,139.62	671.3%
30	188	COMPLERA	ANTIVIRALS	\$41,245	24	\$1,718.54	\$6,687	4	\$1,671.82	563.7%
26	119	COMPOUND DRUG	UNDEFINED	\$46,888	94	\$498.81	\$12,337	58	\$212.71	309.0%
36	99	ISENTRESS	ANTIVIRALS	\$36,495	38	\$960.39	\$14,658	16	\$916.11	167.9%
29	74	MONTELUKAST SODIUM	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$42,985	571	\$75.28	\$19,506	225	\$86.69	137.1%
3	6	REVLIMID	ASSORTED CLASSES	\$176,181	22	\$8,008.25	\$83,335	14	\$5,952.48	127.5%
7	27	HUMIRA	ANALGESICS - ANTI-INFLAMMATORY	\$84,668	33	\$2,565.69	\$43,184	22	\$1,962.90	111.0%
Totals:				\$474,466	803	\$590.87	\$186,126	342	\$544.23	174.3%
Difference Between Periods:				\$288,341	461					



top chains by rxs - UFCW Union & P E HW Fund

Jan 13 - Dec 13													
Curr Rank	Prev Rank	Chain Name	Nbr Pharmacies	Nbr Utilizers	Rxs	Plan Paid Per Rx	Plan Paid	Avg Days Supply	Avg Paid per Day	Pct Generic	Pct Maint	Pct All Specialty	Pct Total Rxs
1	1	SUPERVALU PHARMACIES INC	37	1,837	24,939	\$82.69	\$2,062,231	36.3	\$2.28	72.3%	67.2%	11.4%	39.3%
2	2	CVS PHARMACY INC	285	873	9,218	\$75.20	\$693,222	33.1	\$2.27	77.9%	62.2%	5.8%	14.5%
3	3	GIANT OF MARYLAND	124	542	7,988	\$102.89	\$821,864	39.6	\$2.60	74.8%	65.6%	9.7%	12.6%
4	4	RITE AID CORPORATION	151	342	4,097	\$83.68	\$342,832	33.9	\$2.47	76.3%	68.8%	5.4%	6.5%
5	5	EPIC PHARMACY NETWORK INC	91	185	3,019	\$106.50	\$321,523	33.3	\$3.20	70.5%	63.5%	8.3%	4.8%
6	6	SAFEWAY INC	59	192	2,454	\$94.14	\$231,014	37.5	\$2.51	78.2%	66.0%	4.4%	3.9%
7	7	WALGREENS DRUG STORE	106	221	2,287	\$94.05	\$215,090	36.4	\$2.58	78.7%	60.6%	6.6%	3.6%
8	8	WALMART STORES INC	87	173	1,934	\$67.59	\$130,726	39.4	\$1.72	78.5%	69.2%	0.0%	3.1%
9	9	TARGET CORPORATION	46	109	1,205	\$59.24	\$71,383	36.2	\$1.63	86.3%	62.7%	0.1%	1.9%
10	12	LEADER DRUG STORES INC	25	41	800	\$82.76	\$66,209	32.3	\$2.56	77.8%	67.9%	1.1%	1.3%
		BriovaRx	3	38	263	\$2,396.96	\$630,400	29.7	\$80.57	39.9%	66.9%	33.9%	0.4%
Totals:					58,204	\$95.98	\$5,586,494	36.0	\$2.67	74.6%	65.8%	86.6%	91.8%
Plan Totals:					63,408	\$95.84	\$6,077,280	35.8	\$2.67	74.8%	65.9%		

Savings Incurred Utilization Management Programs 2013



Savings Incurred – Utilization Management Programs

Prior Authorizations

Clinical Programs	Drug Classe(s) Affected	Product(s) Affected	# of Members Affected	# of Rx's Affected	Point of Sale Savings	Average Fill Rate* *	Total Savings based on Average Fill Rate	PMPM	PEPM
Prior Authorizations	ADHD/ ANTI-NARCOLEPSY/ ANTI-OBESITY/ ANOREXIANTS	BELVQ, DIETHYLPROPION HCL ER, PHENDIMETRAZINE TARTRATE, PHENTERMINE HCL, QSYMIA	38	82	\$2,148	4.5	\$4,480	\$0.08	\$0.19
Prior Authorizations	CARDIOVASCULAR AGENTS	CIALIS, LEVTRA, VIAGRA	82	119	\$23,677	4.8	\$78,313	\$1.34	\$3.36
Prior Authorizations	CONTRACEPTIVES	ALYACEN 1/35, ERRIN, GENERESS FE, GIANM, GILDESS 1/20, GILDESS FE 1/20, JUNEL FE 1.5/30, JUNEL FE 1/20, LO LOESTRIN FE, MICROGESTIN FE, NORETHINDRONE, ORSYTHIA, ORTHO EVRA, ORTHO TRI-CYCLEN LO, SPRINTEC 28, TRI-LINYAH, TRI-PREVIFEM	20	42	\$1,619	3.3	\$2,544	\$0.04	\$0.11
Prior Authorizations	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS	AVONEX PEN	1	1	\$9,141	3.2	\$29,252	\$0.50	\$1.25
Prior Authorizations Totals:			141	244	\$36,585.21		\$114,588.63	\$1.95	\$4.91

Prior Authorization Savings – **\$114,588.63**



Savings Incurred – Utilization Management Program

Quantity Limits

Quantity Limits	ANALGESICS - ANTI-INFLAMMATORY	CELEBREX, KETOROLAC TROMETHAMINE	23	26	\$2,018	2.0	\$3,570	\$0.06	\$0.15
Quantity Limits	ANTIEMETICS	ONDANSETRON HCL, ONDANSETRON ODT	72	85	\$1,904	1.4	\$2,258	\$0.04	\$0.10
Quantity Limits	CARDIOVASCULAR AGENTS	MUSE, STAXYN	2	3	\$416	4.8	\$1,331	\$0.02	\$0.06
Quantity Limits	HYPNOTICS	LUNESTA, ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE ER	84	204	\$6,524	4.0	\$10,746	\$0.18	\$0.46
Quantity Limits	MIGRAINE PRODUCTS	NARATRIPTAN HCL, RELPAX, RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE ODT, SUMATRIPTAN SUCCINATE	29	42	\$4,007	2.6	\$7,194	\$0.12	\$0.31
Quantity Limits	ULCER DRUGS	ACIPHEX, DEXILANT, LANSOPRAZOLE, NEXIUM, OMEPRAZOLE, PANTOPRAZOLE SODIUM	29	32	\$3,391	3.7	\$11,370	\$0.19	\$0.49
Quantity Limits	VASOPRESSORS	ALM-Q, EPIPEN 2-PAK, EPIPEN-JR 2-PAK	13	15	\$3,840	1.0	\$3,328	\$0.06	\$0.14
Quantity Limits Totals:			252	407	\$22,100.62		\$39,797.49	\$0.68	\$1.71
Grand Totals:			393	651	\$58,685.83		\$154,386.12	\$2.63	\$6.62

Quantity limits Savings - **\$39,797.49**

Grand Total Savings (Prior Authorizations and Quantity Limits)- \$154,386.12



catamaran

program optimization

Client Name: UFCW Union & P E H W Fund
 Claims Period: Jan 2013 - Dec 2013
 Report: Quantity Limit Savings Model

Current Metrics

Total Utilizers	Rxs	Total Plan Paid	Total Member Cost	Total Gross Cost
3,580	63,117	\$6,050,954	\$508,960	\$6,559,914

Savings by Therapy Class (Top 10)

Rank	Therapeutic Class Name	Estimated Plan Paid Savings	Estimated Rxs Impacted	Avg Plan Paid per Rx	Estimated Members Impact
1	ANTIDEPRESSANTS	\$8,233	191	\$82.77	50
2	ANALGESICS - OPIOID	\$6,583	126	\$122.99	39
3	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREX	\$5,038	41	\$263.79	9
4	ANTIEMETICS	\$2,456	198	\$19.68	142
5	ANTIASTHMATIC AND BRONCHODILATOR AGENTS	\$2,295	62	\$143.38	37
6	OPHTHALMIC AGENTS	\$1,796	43	\$126.62	12
7	ANTIVIRALS	\$1,708	8	\$402.79	2
8	NASAL AGENTS - SYSTEMIC AND TOPICAL	\$1,685	58	\$88.46	34
9	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS	\$1,479	21	\$181.79	4
10	ANTIPSYCHOTICS/ANTIMANIC AGENTS	\$714	13	\$144.00	4
	All Other Classes - 6	\$1,990	63	\$107.56	

Estimated Plan Cost Savings	Estimated Rxs Impacted	Estimated Unique Utilizers Impacted	Estimated Total Savings Percentage
\$33,976	824	331	0.6%

Client Name: UFCW Union & P E H W Fund
 Claims Period: Jan 2013 - Dec 2013
 Report: Quantity Limit Savings Model

Current Metrics

Total Utilizers	Rxs	Total Plan Paid	Total Member Cost	Total Gross Cost
3,580	63,117	\$6,050,954	\$508,960	\$6,559,914

Savings by Therapy Class (Top 10)

Rank	Drug Name	Therapeutic Class Name	Estimated Plan Paid Savings	Estimated Rxs Impacted	Avg Plan Paid per Rx	Estimated Members Impact
1	AMPHETAMINE/DEXTROAMPHETA	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREX	\$2,939	28	\$236.34	8
2	BUPROPION HCL XL	ANTIDEPRESSANTS	\$2,341	34	\$106.96	8
3	TRAMADOL HCL ER	ANALGESICS - OPIOID	\$2,250	21	\$183.47	7
4	VYVANSE	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREX	\$2,099	13	\$322.91	2
5	ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	\$1,963	52	\$93.56	8
6	VIIBRYD	ANTIDEPRESSANTS	\$1,786	7	\$382.68	1
7	FAMCICLOVIR	ANTIVIRALS	\$1,708	8	\$402.79	2
8	MORPHINE SULFATE ER	ANALGESICS - OPIOID	\$1,538	56	\$64.29	6
9	CHANTIX CONTINUING MONTH	PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENT	\$1,479	21	\$181.79	4
10	OPANA ER (CRUSH RESISTANT	ANALGESICS - OPIOID	\$1,447	7	\$583.01	2
	All Other Drugs - 48		\$14,426	577	\$70.36	

Estimated Plan Cost Savings	Estimated Rxs Impacted	Estimated Unique Utilizers Impacted	Estimated Total Savings Percentage
\$33,976	824	331	0.6%

Client Name: UFCW Union & P E H W Fund
 Claims Period: Jan 2013 - Dec 2013
 Report: Prior Authorization Savings Model

Current Metrics

Total Utilizers	Total Rxs	Total Plan Paid
3,580	63,117	\$6,050,954

Savings by Class (Top 10)

Rank	Therapeutic Class Name	Rxs Impacted	Utilizers Impacted	Current Plan Paid for Targeted Opportunities	Estimated Plan Paid Savings
1	ANALGESICS - ANTI-INFLAMMATORY	308	80	\$59,564	\$30,984
2	ANTINEOPLASTICS	32	4	\$157,959	\$24,122
3	ENDOCRINE AND METABOLIC AGENTS - MISC.	27	6	\$59,030	\$15,313
4	DERMATOLOGICALS	57	27	\$19,561	\$12,532
5	ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREX	46	8	\$24,325	\$11,755
6	ANALGESICS - OPIOID	120	20	\$40,779	\$9,685
7	ANTIANGINAL AGENTS	28	6	\$7,615	\$6,127
8	ANTIHYPERLIPIDEMICS	41	10	\$5,797	\$3,427
9	OPHTHALMIC AGENTS	29	17	\$9,866	\$2,345
10	HEMATOPOIETIC AGENTS	2	1	\$7,461	\$2,167
	All Others - 9	69	29	\$29,404	\$8,995

Standard PA Totals	759	208	\$421,361	\$127,453
			Estimated Savings Pct	2.1%
			Estimated Savings PMPM	\$2.17

Client Name: UFCW Union & P E H W Fund
 Line of Business: Carrier - UFCWUPE
 Claims Period: Jan 2013 - Dec 2013
 Report: Standard Step Therapy Savings Model

Current Metrics:-

Total Utilizers	32163	Total Plan Paid	Total Member Cost	Total Gross Cost
3,580	63,117	\$6,050,954	\$508,960	\$6,559,914

Savings by Category:

Step Therapy Class Name	Targeted Drugs Plan Paid	Percent of Total Plan Paid	Target Drugs Plan Paid per 30 day Rx	First Line Drugs Plan Paid per 30 day Rx	Estimated Plan Paid Savings	Estimated Members Impact
ARBs	\$2,665	0.0%	\$83.40	\$75.60	\$254	3
Intranasal Steroids	\$2,494	0.0%	\$162.90	\$56.40	\$938	8
PPIs	\$62,040	1.0%	\$312.60	\$93.00	\$24,881	27
SSRIs	\$11,938	0.2%	\$192.00	\$20.40	\$5,934	6
Triptans	\$370	0.0%	\$616.20	\$153.60	\$157	2

Estimated Plan Cost Savings	Estimated Total Savings Percentage	Estimated Member Savings Percentage
\$32,163	0.5%	0.4%

Client Name: UFCW Union & P E H W Fund
 Line of Business: Carrier - UFCWUPE
 Claims Period: Jan 2013 - Dec 2013
 Report: Standard Step Therapy Savings Model Top Drugs Report

Opportunity by Drug:

	Drug Name	Step Therapy Class Name	Rx Count
1	EDARBYCLOR	ARBs	15
2	EDARBI	ARBs	3
3	BECONASE AQ	Intranasal Steroids	4
4	DYMISTA	Intranasal Steroids	3
5	ZETONNA	Intranasal Steroids	3
6	OMNARIS	Intranasal Steroids	2
7	ACIPHEX	PPIs	158
8	ZEGERID	PPIs	10
9	PREVACID SOLUTAB	PPIs	7
10	VIIIBRYD	SSRIs	44
11	LUVOX CR	SSRIs	11
12	ALSUMA	Triptans	1
13	FROVA	Triptans	1

Strategic Planning 2014



Strategic Planning

- Updating **Utilization Management program** recommendations –
 - Prior Authorizations – savings – \$127,453
 - Quantity limits – savings –\$33,976
 - Step therapy – savings - \$32,163
- Implementing **RetroDur program** – captures drug conflicts due to major drug interactions, overuse/misuse of drugs (narcotics), duplication of therapy, inappropriate drug dosages and duration of therapy to prevent complications, ER visits and hospitalizations – significant cost savings and safety measures
- **MTM program** – high risk/high cost members are evaluated and interventions are made to prevent overuse and misuse of medications leading to complications
- **Medication Adherence program** – increases compliance on maintenance medications for chronic disease states – Diabetes, Hypertension and Cholesterol to prevent complications and hospitalizations



catamaran

Drug Pipeline Update



Pipeline Update: *Traditional Brand Pipeline*

New Drugs Pending FDA Approval Q1 2014

Trade Name	Generic Name	Company(ies)	Route	Indication/ Use
GRASTEK	Timothy Grass Pollen extract; Phleum pratense	Merck; ALK-Abello	Sublingual	Allergic Rhinitis
HETLIOZ	tasimelteon	Vanda; Bristol Myers Squibb	Oral	Non-24 Hour Disorder
STRIVERDI RESPIMAT	olodaterol	Boehringer Ingelheim	Inhalation	COPD
NORTHERA	droxidopa	Chelsea Therapeutics	Oral	Neurogenic Orthostatic Hypotension (NOH)
NEXIUM OTC	esomeprazole	Pfizer Consumer Health	Oral	Heartburn
RAGWITEK	ALK Ragweed Tablet; Ambrosia artemisiifolia	Merck; ALK-Abello	Sublingual	Allergies
IMPAVDO	miltefosine	Paladin	Oral	Leishmaniasis
TBD	empagliflozin	Boehringer Ingelheim; Eli Lilly	Oral	Type 2 Diabetes Mellitus (DM)

List focuses on New Molecular Entities and High Profile drugs



Pipeline Update: *Specialty Brand Pipeline*

New Drugs Pending FDA Approval Q1 2014

Trade Name	Generic Name	Company(ies)	Route	Indication/ Use
COPAXONE (new formulation)	glatiramer acetate	Teva	Subcutaneous	Relapsing Remitting Multiple Sclerosis (RRMS)
MYALEPT	metreleptin	Bristol Myers Squibb; AstraZeneca	Subcutaneous	Lipodystrophy
VIMIZIM	elosulfase alfa	BioMarin	Intravenous	Mucopolysaccharidosis IVA (Morquio syndrome)
TBD	apremilast	Celgene	Oral	Active Psoriatic Arthritis

List focuses on New Molecular Entities and High Profile drugs



Pipeline Update: Anticipated Generic Approvals/Launches/Patent Expirations Q1 2014

Trade Name (generic name) Company(ies)	Therapeutic Use(s)	Estimated U.S. Sales [†]	Anticipated Generic Availability	Anticipated Launch Type
DIOVAN (valsartan) Novartis	Hypertension; Heart Failure; Reduction of Cardiovascular Mortality after Myocardial Infarction	\$2.1 billion	H1 2014	Exclusive
VALCYTE (valganciclovir hydrochloride) Roche	Cytomegalovirus (CMV) Disease and Infection; CMV Retinitis	\$195 million	Q1 2014	Exclusive
ADVICOR (niacin/lovastatin) AbbVie	Hyperlipidemia	\$42 million	Q1 2014	Exclusive
XELODA (capecitabine) Roche	Breast Cancer; Colorectal Cancer	\$300 million	Q1 2014	Exclusive
ASACOL (mesalamine) Warner Chilcott	Ulcerative Colitis	\$460 million	January 2014	Exclusive with Authorized Generic

[†]Financial data compiled from available annual and quarterly pharmaceutical company reports, IMS Health, Thomson Cortellis, analyst reports, and company press releases.

Launch type information

Authorized Generic = An "authorized generic drug" is a listed drug as defined in § 314.3 that has been approved under subsection 505(c) of the Federal Food, Drug and Cosmetic (FD&C) act and is marketed, sold, or distributed directly or indirectly to retail class of trade with either labeling, packaging (other than repackaging as the listed drug in blister packs, unit doses, or similar packaging for use in institutions), product code, labeler code, trade name, or trade mark that differs from that of the listed drug. For FDA listing of authorized generics, please visit: <http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm126391.htm>;

Competitive (also referred to as "multisource") = Denotes that more than one generic manufacturer is eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval;

Exclusive = Denotes that one generic manufacturer will be eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval. Typically, the exclusive generic manufacturer will be eligible for a 180-day period of marketing exclusivity beginning either from the date it begins commercial marketing of the generic drug product, or from the date of a court decision finding the patent invalid, unenforceable or not infringed, whichever is first.



Pipeline Update: Anticipated Generic Approvals/Launches/Patent Expirations Q1 2014 continued...

Trade Name (generic name) Company(ies)	Therapeutic Use(s)	Estimated U.S. Sales†	Anticipated Generic Availability	Anticipated Launch Type
RAPAMUNE Oral Tab (sirolimus) Wyeth/Pfizer	Prevention of Organ Transplant Rejection	\$231 million	January 2014	Exclusive
AVELOX (moxifloxacin) Schering/Merck	Bacterial Infections	\$376 million	February 2014	Exclusive
HECTOROL (doxercalciferol) Genzyme	Hyperparathyroidism	\$41 million	February 2014	Exclusive
EVISTA (raloxifene) Eli Lilly	Osteoporosis; Reduction in Risk of Invasive Breast Cancer	\$700 million	March 2014	Unknown
RENVELA (sevelamer carbonate) Genzyme	Hyperphosphatemia Associated with Chronic Kidney Disease	\$200 million	March 2014	Exclusive

†Financial data compiled from available annual and quarterly pharmaceutical company reports, IMS Health, Thomson Cortellis, analyst reports, and company press releases.

Launch type information:

Authorized Generic = An "authorized generic drug" is a listed drug as defined in § 314.3 that has been approved under subsection 505(c) of the Federal Food, Drug and Cosmetic (FD&C) act and is marketed, sold, or distributed directly or indirectly to retail class of trade with either labeling, packaging (other than repackaging as the listed drug in blister packs, unit doses, or similar packaging for use in institutions), product code, labeler code, trade name, or trade mark that differs from that of the listed drug. For FDA listing of authorized generics, please visit:

<http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm126391.htm>;

Competitive (also referred to as "multisource") = Denotes that more than one generic manufacturer is eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval;

Exclusive = Denotes that one generic manufacturer will be eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval. Typically, the exclusive generic manufacturer will be eligible for a 180-day period of marketing exclusivity beginning either from the date it begins commercial marketing of the generic drug product, or from the date of a court decision finding the patent invalid, unenforceable or not infringing, whichever is first.




catamaran

Catamaran Formulary Advantage



Formulary Advantage: Overview

Our Formulary Advantage (FA) program Encourages the selection of clinically effective, lower-cost medications.



**Comprehensive,
Unbiased Approach**

19 therapeutic classes,
national independent
P&T committee



**Improved Cost
Savings
Opportunities**

Increasing GDR, not
chasing rebates, drives
optimal drug mix



**Seamless Member
Transition**


Communication
followed by soft and
hard edits



Formulary Advantage: *How We Minimize Disruption*

Prior to any Rx formulary change, Catamaran will go through a multi-step process to inform members, facilitate the transition and minimize disruption.

Formulary changes reviewed quarterly for new medications, annually for drug revisions/deletions



For each notification campaign, the member receives an automated call before and after they receive a letter.



catamaran

Catamaran RetroDUR



RetroDUR Program: Overview

Catamaran's RetroDUR product packages focus on trending therapeutic classes, identification of clinical opportunities and prescription savings based value.

- **Clinical impact:** target clinical opportunities within trending therapeutic classes
- **Risk mitigation:** prevent members from migrating to the highest risk population tier
- **Prescription Savings:** Prescription Savings ROI for Safe & Appropriate Utilization product

RetroDUR Clinical Products

Safe & Appropriate Utilization

- Discontinuation of unsafe and clinically inappropriate therapy drives rich prescription savings

Abused Medications

- Reduce the risks associated with narcotic and controlled substance overuse

Gaps in Care

- Close gaps in medication therapy for treating chronic disease

RetroDUR clinical product features:

- » Sophisticated analytics: extensive set of conflict rules to identify at risk members
- » Timely interventions: daily evaluation of prescription claims data
- » Integration of Medical and other data: accurate identification, minimal false positives
- » Prescriber focused interventions: strong clinical and cost impact with no disruption to members



catamaran

Catamaran MTM Program

MTM Program: Overview


Catamaran's MTM Program identifies high risk/high cost members & conducts interventions to drive healthy outcomes.

- MTM program will conduct 1:1 interventions and **actively monitor** client's membership for high \$ and complex cases
- Addresses **100%** of all qualified MTM members
 - » **Face-face** member consultation through 18,000+ network pharmacies
 - » **Telephonic outreach** through dedicated Clinical Intervention Center
 - » Utilizes **multi-channel interventions** to drive completion rate for Comprehensive Medication Review (CMR)
- **Configurability** based on client-specific needs
 - » Flexible qualification criteria thresholds
 - » Flexibility available within the MTM service categories



MTM Program: *New IVR Enhancement*

Catamaran's new IVR enhancement will help drive increased participation from members receiving Comprehensive Medication Review.





MTM Program: *New Video Consultation Capability*

Using new technology, Catamaran MTM pharmacists are able to provide hands-on medication counseling services.



**MTM Pharmacist
Consultation**



Skype and Facetime



**Satisfaction
Measurement**

Targeted Members: Members whose case review resulted in a change in medication recommended to the Physician and the Physician approved the recommendation, for Comprehensive Medication Review (CMR) and Targeted Medication Review (TMR).



MTM Program: *Demonstrable ROI & Reporting*

Catamaran's MTM programs include ROI guarantees & robust reporting.

2012 MTM BoB Outcomes	
Comprehensive Medication Review (CMR) Return on Investment (ROI)	2 : 1
Per Intervened Member Per Month Savings	\$33.48
Completion Rate	40%
Gaps in Care ROI	5.2 : 1
Per Intervened Member Per Month Savings	\$34.10
High Risk Medications ROI	4.3 : 1
Per Intervened Member Per Month Savings	\$17.90
Lives	440K

- Prospective analysis reporting
- Extensive and tailored reports to fit client needs
- MTM Targeted Medication Review reports
 - » Quarterly
 - » Activity metrics
 - » Outcomes
- MTM Comprehensive Medication Review report
 - » Semi-annual
 - » Activity metrics
 - » Outcomes



catamaran

Catamaran Medication Adherence Program



Catamaran Medication Adherence Solution: Overview

Member and prescriber outreach programs that improves medication adherence through:

Identifying the Right Member

Using risk assessment, claims data & analytics

Intervening at the Right Time

Triggered by new-to-therapy, late-to-refill & low adherence rates

Utilizing the Right Communications

IVR, live agent, Mobile App, email, mailings & virtual consultation

OPTION



Member Outreach

- **Member** interventions through IVR, mail, email, mobile app & 1:1 telephonic pharmacist consult
- Targets 3 disease states: **Diabetes, Hypertension, Cholesterol**

OPTION



Member & Prescriber Outreach

- **Member** interventions through IVR, mail, mobile app & 1:1 telephonic pharmacist consult
- **Prescriber** outreach through fax
- Targets 15 disease states including: **Diabetes, Hypertension, Cholesterol, Depression/Mental Health, HIV, Transplant**

OPTION



Star Outreach

- **Member & Prescriber** interventions through IVR, mail, mobile app, 1:1 telephonic or virtual pharmacist consult and fax
- **Star Measures:** Adherence, High Risk Medications and Diabetes Care
- Targets 3 disease states: **Diabetes, Hypertension, Cholesterol**

Catamaran Medication Adherence Solution

Program 1: Member Outreach

	New to Therapy	Late to Refill	Low Adherence Rate*
Distinct Member Identification	New medication not identified in member Rx claims history in the past 180 days	Members identified as 2 days late to fill	Using PDC, members identified if PDC is below 80%
Effective Member Engagement	OUTREACH: MAIL Educational mailing with drug & disease state information	OUTREACH: IVR Outbound IVR with direct transfer to pharmacy option; 2 nd IVR call if 10 days late to fill	OUTREACH: IVR, EMAIL & 1:1 PHARMACIST CONSULT Outbound IVR with option to speak with Catamaran pharmacist or informative email
Complimentary adherence support via Catamaran Mobile App			

Disease state focus: *Diabetes, Hypertension, Cholesterol*

* PDC = Proportion of Days Covered. Low Adherence Rate calculated using PDC

Catamaran Medication Adherence Solution

Program 2: Member & Prescriber Outreach

	New to Therapy	Late to Refill	Comprehensive Outreach*
Distinct Member Identification	New medication not identified in member Rx claims history in the past 180 days	Members identified as 2 days late to fill	Members identified as being non-adherent if PDC is below 80%
Effective Member & Provider Engagement	OUTREACH: MAIL Educational mailing with drug & disease state information	OUTREACH: IVR Outbound IVR with direct transfer to pharmacy option; 2 nd IVR call if 10 days late to fill	OUTREACH: FAX, MAIL, IVR & 1:1 PHARMACIST CONSULT Providers: initial & follow-up fax Members: letter sent 1 week post prescriber fax; outbound IVR; pharmacist consult option
Complimentary adherence support via Catamaran Mobile App			

Disease State Focus:

- New to Therapy & Late to Refill: *Diabetes, Hypertension, Cholesterol*
- Comprehensive Outreach: *Diabetes, Hypertension, Cholesterol, Depression/Mental health, Transplant, Seizures, Cardiovascular, Osteoporosis, Respiratory, Parkinson's, Alzheimer's Disease, Benign Prostatic Hyperplasia (BPH), Autoimmune & Oral Chemotherapy*

* PDC = Proportion of Days Covered used to calculate non-adherence in Comprehensive Outreach

Catamaran Medication Adherence Solution

Program 3: Star Outreach

	New to Therapy	Late to Refill	Integrated Outreach
Distinct Member Identification	New medication not identified in member Rx claims history in the past 180 days	Members identified as 2 days late to fill	Members not meeting Part D Star measures: High Risk Medications, Diabetes Treatment and Medication Adherence
Effective Member Engagement	OUTREACH: MAIL Educational mailing with drug & disease state information	OUTREACH: IVR Outbound IVR with direct transfer to pharmacy option; 2 nd IVR call if 10 days late to fill	OUTREACH: Fax, Mail, IVR & 1:1 PHARMACIST CONSULT Providers: initial & follow-up fax Members: letter, IVR, pharmacist consult option
Complimentary adherence support via Catamaran Mobile App			

Disease state focus: *Diabetes, Hypertension and Cholesterol. High Risk Medications:* *Drug Class based on CMS High Risk Medication list*

* PDC = Proportion of Days Covered used to calculate non-adherence in Integrated Outreach



catamaran

Catamaran Specialty News and Update



Specialty News and Update: *New Facility in Jeffersonville, IN*

Investing in new locations to better serve our customers

- Catamaran's newest Specialty facility is located in Jeffersonville, IN
 - » Over 300 employees will work at the Jeffersonville location
 - » The 105,000 square foot facility adds an additional capacity of 1,500 Rx/day to our existing facilities
 - » Planned enhancements to pick and pack technology at this facility will further increase capacity by an additional 1,500 Rx/day
 - » Proximity to UPS World Headquarters provides direct access to logistics and delivery services including next day fulfillment up until midnight
- Notable areas of investment include:
 - » Expansion of our therapy footprint to Infused Therapies
 - » Continuation of our limited drug distribution activities
 - » Ongoing R&D investments related to Medical Management and new technology
 - » 10 BrivoRx Live counseling rooms for specialty video consultations



Specialty News and Update: *BriovaRx Live*

Our video consult capability provides education with a personalized touch



Video Consult Checklist

- Review medications & supplies
- Assemble device (if needed)
- Injection training
- Storing procedures
- Side effects
- Drug interactions
- Questions
- Support & reassurance



BriovaRx Live: Patient Consult via Video